CGRP-Antagonist Compounds for Migraine Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current CGRP-antagonists for treating migraine and other conditions have limitations in efficacy and side effects, and there is a need for more effective compounds with improved pharmacological properties.
Innovation Solution
Development of specific compounds of general formula I, which are CGRP-antagonists, including various structural embodiments and their physiologically acceptable salts, that exhibit strong affinities for CGRP receptors and display effective antagonistic properties in pharmacological tests.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current CGRP-antagonists are used for treating migraine, then treatment is provided, but efficacy is limited and side effects occur
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of CGRP-antagonist compounds through systematic variation of substituents at specific positions (R1, R2, R3, R4, X groups) to optimize the balance between efficacy and side effects. This involves changing molecular parameters such as hydrophobicity, steric bulk, and electronic properties to improve therapeutic index
Solution Approach 2:
The patent employs composite molecular structures combining multiple functional groups (amino acids, aromatic rings, heterocyclic systems, carboxylic acid derivatives) in specific configurations to create CGRP-antagonists with enhanced pharmacological properties. The composite nature of these molecules allows simultaneous optimization of binding affinity and reduced off-target effects
2Reliability
If CGRP-antagonist compounds are developed with stronger affinity, then antagonistic activity increases, but molecular complexity increases
Solution Approach 1:
The patent applies segmentation by dividing the CGRP-antagonist molecule into distinct functional domains: an N-terminal region with specific amino acid sequences, a central hydrophobic core with variable substituents, and a C-terminal region containing carboxylic acid groups. This modular architecture allows independent optimization of each segment for binding affinity while maintaining overall structural manageability
Solution Approach 2:
The patent implements local quality by introducing specific functional groups at predetermined positions within the molecular structure. Each substituent (R1-R4) is strategically placed to provide localized interactions with specific residues in the CGRP receptor binding pocket, enhancing affinity without requiring global structural complexity
Data Source
AI summary
The present invention relates to the CGRP-antagonists of general formula Iwherein R1, R2, R3, R4 and X are defined as in claim 1, the tautomers, the isomers, the diastereomers, the enantiomers, the hydrates, mixtures and salts thereof and the hydrates of the salts, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases, as well as those compounds of general formula I in which one or more hydrogen atoms are replaced by deuterium, pharmaceutical compositions containing these compounds, the use thereof and processes for the preparation thereof.